All In Biotech

Drug Trial Radar · NCT06897358

Leniolisib for Immune Dysregulation in CVID

A Study to Assess Safety and Tolerability, and Explore Efficacy of Leniolisib for Immune Dysregulation in Common Variable Immunodeficiency (CVID)

Last checked: Nov 20, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

27

Actual

Start

Feb 12, 2025

Primary completion

Aug 12, 2026

Study completion Aug 12, 2026

Sponsor

Lead sponsor
Pharming Technologies B.V.Industry
Sponsor type
Industry
Collaborators
Lahey Hospital & Medical Center
First posted
Mar 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study, common variable immunodeficiency (CVID) patients will all receive the study drug, leniolisib, for a treatment period of 6 months. Participants will start on a lower dose of leniolisib, followed by a mid and then a higher dose level. The primary goal is to assess the safety and tolerability of leniolisib, and secondary goal is to assess the potential for leniolisib to provide benefits for patients.

Conditions

  • Common Variable Immunodeficiency (CVID)

Interventions

  • LeniolisibDrug

    Planned dose will range from 10 mg twice daily to 70 mg twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety & TolerabilityTime frame: From baseline to the end of 24 weeks of treatment

Locations

7 sites in 3 countries. Site status is shown where the registry gives one.

  • Children's Hospital Colorado

    Aurora, Colorado

  • National Institute of Health

    Bethesda, Maryland

  • Lahey Hospital & Medical Center

    Burlington, Massachusetts

  • Mount Sinai Hospital

    New York, New York

  • Texas Children's Hospital

    Houston, Texas

  • IIS La Fe

    Valencia, Spain

  • Leeds Teaching Hospital NHS Trust

    Leeds, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.